2. Search Result
Search Result
Results for "

glucose-stimulated

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

1

Biochemical Assay Reagents

7

Peptides

10

Natural
Products

11

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W040329
    2'-Deoxyadenosine

    		Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine
  • HY-175701
    CT-996

    RO7795081; RG6652

    		 Arrestin GLP Receptor Metabolic Disease
    CT-996 is an orally active GLP-1RA agonist with an EC50 of 0.49 nM. CT-996 reduces the recruitment of β-arrestin and the internalization of GLP-1R. CT-996 suppresses postprandial blood glucose in mice expressing human GLP-1 receptors and enhances glucose-stimulated insulin secretion (GSIS) in obese monkeys during intravenous glucose challenge. CT-996 can be used for the research of type 2 diabetes (T2D) and obesity .
    CT-996
  • HY-N0847
    Micheliolide
    5+ Cited Publications

    		 NF-κB PI3K Akt TGF-beta/Smad Inflammation/Immunology Cancer
    Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .
    Micheliolide
  • HY-119322
    Tifenazoxide

    NN414

    		 Potassium Channel Metabolic Disease
    Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide
  • HY-W011683
    2'-Deoxyadenosine monohydrate

    		Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate
  • HY-P3954
    Somatostatin-28 (sheep, human rat mouse)

    		Somatostatin Receptor Metabolic Disease
    Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
    Somatostatin-28 (sheep, human rat mouse)
  • HY-B1021
    Vincamine
    1 Publications Verification

    		 Free Fatty Acid Receptor Cardiovascular Disease Metabolic Disease
    Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .
    Vincamine
  • HY-N6005
    Methyl caffeate

    		Bacterial Fungal Apoptosis Bcl-2 Family Infection Metabolic Disease Cancer
    Methyl caffeate is a phenylpropanoid, antibacterial agent, and Apoptosis-inducing agent. Methyl caffeate can be isolated from the flowers of peach Prunus persica (L.). Methyl caffeate upregulates the expression of pro-apoptotic proteins Bid, Bax and p53, and downregulates the expression of anti-apoptotic protein BCL-2. Methyl caffeate downregulates SASP factors. Methyl caffeate enhances glucose-stimulated insulin secretion. Methyl caffeate inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, fungi, and Mycobacterium tuberculosis strains. Methyl caffeate can be used in studies related to breast cancer, type 2 diabetes, and tuberculosis .
    Methyl caffeate
  • HY-14363
    TUG-424

    		Free Fatty Acid Receptor Metabolic Disease
    TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    TUG-424
  • HY-W040329R
    2'-Deoxyadenosine (Standard)

    		Reference Standards Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine (Standard) is the analytical standard of 2'-Deoxyadenosine (HY-W040329). This product is intended for research and analytical applications. 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine (Standard)
  • HY-176040
    IXA62

    		IRE1 Amyloid-β Neurological Disease Metabolic Disease
    IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells .
    IXA62
  • HY-N9685
    Digitoxose

    D-(+)-Digitoxose

    		 Others Metabolic Disease
    Digitoxose (D-(+)-Digitoxose), a natural product, specifically and competitively inhibits glucose-stimulated insulin release from islets in lean and obese mice. Digitoxose can be used in diabetes research .
    Digitoxose
  • HY-W040329S1
    2'-Deoxyadenosine-13C10

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine- 13C10 is 13C-labeled 2'-Deoxyadenosine (HY-W040329) . 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine-13C10
  • HY-P2378
    Neuromedin U-25 (human)

    		Endogenous Metabolite Cardiovascular Disease
    Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .
    Neuromedin U-25 (human)
  • HY-P1427A
    Guangxitoxin 1E TFA

    		Potassium Channel Neurological Disease
    Guangxitoxin 1E TFA is the TFA salt form of Guangxitoxin 1E (HY-P1427). Guangxitoxin 1E TFA is a peptide toxin and a selective inhibitor for voltage-gated potassium channel KV2.1 and KV2.2 with IC50 of 1-3 nM. Guangxitoxin 1E TFA enhances glucose-stimulated intracellular calcium ion oscillations and increases insulin secretion in a glucose-dependent manner .
    Guangxitoxin 1E TFA
  • HY-179041
    SZ0232

    		PGE synthase Prostaglandin Receptor MDM-2/p53 Amino acid Transporter Glutathione Peroxidase Ferroptosis Metabolic Disease Endocrinology
    SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease .
    SZ0232
  • HY-125662A
    BMX-001

    		Reactive Oxygen Species (ROS) Apoptosis Metabolic Disease
    BMX-001, a novel redox-active metalloporphyrin, improves islet function and engraftment in a murine transplant model. BMX-001 reduces apoptosis in human and murine islets. BMX-001 significantly improves static-glucose stimulated insulin secretion (sGSIS) responses in murine islets. BMX-001 can significantly restore euglycemia in murine islet studies in the presence of the MnSOD. BMX-001 reduces the generation of ROS in a murine islet isolation and culture model .
    BMX-001
  • HY-143401
    Hit 1

    		IDE Metabolic Disease
    Hit 1 is an activator of ansulin degrading enzyme (IDE), with an EC50 of 5.5 μM. Hit 1 can decrease glucose-stimulating insulin secretion .
    Hit 1
  • HY-158584
    13-OAHSA

    9Z-Octadecenoic acid, 12-carboxy-1-pentyldodecyl ester

    		 Endogenous Metabolite Metabolic Disease
    13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .
    13-OAHSA
  • HY-158583
    13-POHSA

    		Endogenous Metabolite Metabolic Disease
    13-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .
    13-POHSA
  • HY-W011683S6
    2'-Deoxyadenosine monohydrate-13C10,15N5 hydrate

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate- 13C10, 15N5 is the 13C and 15N labeled 2'-Deoxyadenosine monohydrate (HY-W011683) . 2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate-13C10,15N5 hydrate
  • HY-124771
    RH01386

    		Apoptosis Metabolic Disease
    RH01386 is a small molecule that can prevent endoplasmic reticulum stress (ERS)-induced β cell dysfunction and death, and inhibits proapoptotic gene expression. RH01386 restores ERS-impaired glucose-stimulated insulin secretion responses. RH01386 has the potential for type 2 diabetes treatment .
    RH01386
  • HY-158650
    10-OAHSA

    		Endogenous Metabolite TNF Receptor Inflammation/Immunology Endocrinology
    10-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 10-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration. 10-OAHSA reduces LPS (HY-D1056)-induced Tnf-α secretion in bone marrow-derived dendritic cells (BMDCs) .
    10-OAHSA
  • HY-Q40876
    BBT

    		Calcium Channel Metabolic Disease
    BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ (HY-13753))-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .
    BBT
  • HY-P1184
    HNGF6A

    		Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Metabolic Disease
    HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .
    HNGF6A
  • HY-P10337
    OXM-7

    		GCGR GLP Receptor Metabolic Disease Endocrinology
    OXM-7 is a dual agonist of GLP-1R (EC50=0.024 nM) and GCGR (EC50=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .
    OXM-7
  • HY-W011683S3
    2'-Deoxyadenosine monohydrate-5′-13C

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate-5′- 13C is the 13C labeled 2'-Deoxyadenosine monohydrate (HY-W011683) . 2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate-5′-13C
  • HY-W011683S
    2'-Deoxyadenosine monohydrate-1′-13C

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate-1′- 13C is the 13C labeled 2'-Deoxyadenosine monohydrate (HY-W011683) . 2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate-1′-13C
  • HY-160602
    CPL207280

    		Free Fatty Acid Receptor Metabolic Disease
    CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
    CPL207280
  • HY-170867
    Nrf2/HO-1 activator 3

    		Keap1-Nrf2 Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Cardiovascular Disease
    Nrf2/HO-1 activator 3 (Compound C3a) is the activator for Nrf2 signaling pathway that promotes the Nrf2 translocation into nuclei and upregulates the expression of heme oxygenase-1 HO-1. Nrf2/HO-1 activator 3 inhibits the overespression of ROS and MDA in H2O2- or glucose-stimulated H9c2 cardiomyocytes, inhibits the cell viability and colony formation, thereby exhibiting antioxidant efficacy .
    Nrf2/HO-1 activator 3
  • HY-115606
    ML077

    		NKCC Endogenous Metabolite Neurological Disease
    ML007 is a selective antagonist targeting the neuron-specific potassium-chloride co-transporter 2 (KCC2) with an IC50 for KCC2 is 537 nM, while its inhibitory activity on KCC1 is extremely weak (IC50 > 50 μM). ML077 inhibits the chloride ion excretion function of KCC2, increasing the intracellular chloride ion concentration, thereby enhancing the depolarization mediated by chloride ion channels. ML007 can promote glucose-stimulated insulin secretion (GSIS) without relying on KATP channels. ML007 can be used to study the functions related to pain, epilepsy, and insulin secretion .
    ML077
  • HY-111141
    AM-3189

    		Free Fatty Acid Receptor Metabolic Disease
    AM-3189 is an orally active and selective GPR40 agonist with EC50 values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes .
    AM-3189
  • HY-178967
    DRAK1/2-IN-2

    		DAPK Apoptosis Interleukin Related Endogenous Metabolite Metabolic Disease
    DRAK1/2-IN-2 (Compound Y17) is a DRAK1/2 inhibitor with IC50 values for DRAK2 and DRAK1 of 353.2 nM and 507.4 nM respectively. DRAK1/2-IN-2 can enhance mitochondrial membrane potential and glucose-stimulated insulin secretion (GSIS). DRAK1/2-IN-2 resists lipotoxicity-induced cell apoptosis. DRAK1/2-IN-2 significantly inhibits the secretion of pro-inflammatory cytokine IL-1β, thereby exerting an anti-inflammatory effect. DRAK1/2-IN-2 can significantly lower the blood glucose levels of mice. DRAK1/2-IN-2 can be used in diabetes research.
    DRAK1/2-IN-2
  • HY-P1184A
    HNGF6A TFA

    		Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Metabolic Disease
    HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo .
    HNGF6A TFA
  • HY-158639
    12-POHSA

    		Endogenous Metabolite Metabolic Disease
    12-POHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 12-POHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .
    12-POHSA
  • HY-B1021R
    Vincamine (Standard)

    		Reference Standards Free Fatty Acid Receptor Cardiovascular Disease Metabolic Disease
    Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .
    Vincamine (Standard)
  • HY-W778207
    2'-Deoxyadenosine-13C5 monohydrate

    		Isotope-Labeled Compounds Others
    2'-Deoxyadenosine- 13C5 monohydrate is the 13C labeled isotope of '-Deoxyadenosine monohydrate (HY-W040329). 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine-13C5 monohydrate
  • HY-W745905
    2'-Deoxyadenosine-15N1

    		Isotope-Labeled Compounds Apoptosis Nucleoside Antimetabolite/Analog Caspase Endogenous Metabolite Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine- 15N1 is the 15N-labeled 2'-Deoxyadenosine (HY-W040329). 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine-15N1
  • HY-W011683S7
    2'-Deoxyadenosine monohydrate-15N5

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate- 15N5 is the 15N labeled 2'-Deoxyadenosine monohydrate (HY-W011683) . 2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate-15N5
  • HY-W011683R
    2'-Deoxyadenosine monohydrate (Standard)

    		Reference Standards Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate (Standard) is the analytical standard of 2'-Deoxyadenosine monohydrate ((HY-W011683). This product is intended for research and analytical applications. 2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate (Standard)
  • HY-W011683S1
    2'-Deoxyadenosine monohydrate-2′-13C

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate-2′- 13C is the 13C labeled 2'-Deoxyadenosine monohydrate(HY-W011683) . 2′-Deoxyadenosine monohydrate is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer .
    2'-Deoxyadenosine monohydrate-2′-13C
  • HY-W040329S
    2'-Deoxyadenosine-13C10,15N5

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine- 13C10, 15N5 is 13C and 15N-labeled 2'-Deoxyadenosine (HY-W040329) . 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine-13C10,15N5
  • HY-W011683S2
    2'-Deoxyadenosine monohydrate-3′-13C

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine monohydrate-3′- 13C is the 13C labeled 2'-Deoxyadenosine monohydrate (HY-W011683) glucose-stimulated insulin release. 2′-Deoxyadenosine monohydrate inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine monohydrate activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine monohydrate inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine monohydrate inhibits the growth of various cells. 2'-Deoxyadenosine monohydrate has an anticancer effect on colon cancer>
    2'-Deoxyadenosine monohydrate-3′-13C
  • HY-W040329S3
    2'-Deoxyadenosine-15N5,d13

    		Isotope-Labeled Compounds Endogenous Metabolite Nucleoside Antimetabolite/Analog Caspase Apoptosis Metabolic Disease Endocrinology Cancer
    2'-Deoxyadenosine- 15N5,d13 is deuterium and 15N labeled 2'-Deoxyadenosine (HY-W040329) . 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer .
    2'-Deoxyadenosine-15N5,d13
  • HY-P3608
    [Des-His1,Glu9] Glucagon

    		GCGR Metabolic Disease
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
    [Des-His1,Glu9] Glucagon
  • HY-12976
    DS-1558

    		G Protein-coupled Receptor Kinase (GRK) Metabolic Disease
    DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .
    DS-1558
  • HY-N0847R
    Micheliolide (Standard)

    		Reference Standards NF-κB PI3K Akt TGF-beta/Smad Inflammation/Immunology Cancer
    Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .
    Micheliolide (Standard)
  • HY-119322R
    Tifenazoxide (Standard)

    NN414 (Standard)

    		 Potassium Channel Reference Standards Metabolic Disease
    Tifenazoxide (Standard) is the analytical standard of Tifenazoxide. This product is intended for research and analytical applications. Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective KATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide (Standard)
  • HY-153667
    MK-2305

    		Free Fatty Acid Receptor Metabolic Disease
    MK-2305 is an orally active GPR40 partial agonist with an EC50 of 6 nM in rats. MK-2305 mediates glucose-stimulated insulin secretion and inhibits endogenous glucose production by reducing gluconeogenesis from tricarboxylic acid (TCA) cycle substrates. MK-2305 increases plasma insulin levels under hyperglycemic and glucose-stimulated conditions, reduces fasting blood glucose, and improves glucose homeostasis. MK-2305 can be used in studies related to type 2 diabetes .
    MK-2305
  • HY-182580
    HBK001

    		GPR119 Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    HBK001 is an orally active and selective dual GPR119 agonist and DPP-IV inhibitor. HBK001 triggers cAMP production, PKA activation, CREB phosphorylation, glucose-stimulated insulin secretion, plasma incretin elevation, β-cell proliferation, and β-cell function gene up-regulation. HBK001 reduces blood glucose, ameliorates hyperglycemia, improves glucose tolerance, and enhances islet morphology. HBK001 can be used for the research of type 2 diabetes mellitus .
    HBK001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: